Cosmos Holdings Inc. - COSM STOCK NEWS

Cosmos Health (NASDAQ:COSM) announced its agreement to acquire the remaining rights to a CNS cancer drug patent filed with WIPO under PCT/EP2023/071865. This acquisition follows the December 2023 agreement where Cosmos Health had secured 60% of the rights. The National Hellenic Research Foundation, a major Greek research entity, will continue supporting Cosmos Health during the transition. This move aims to bolster Cosmos Health's position in the global brain tumor treatment market, projected to grow from $3.1 billion in 2023 to $6.2 billion by 2033. CEO Greg Siokas highlighted the importance of this acquisition in addressing the rising incidence of CNS cancers and the needs of the aging population. This initiative is complemented by recent hires and the strategic acquisition of Cloudpharm to enhance R&D capabilities with AI-aided drug repurposing technologies.

Cosmos Health (NASDAQ:COSM), a global healthcare group, has acquired Pelofarm's pharmacy distribution network in Arcadia, Greece. This strategic move is expected to boost Cosmos Health's annual revenue by over $5 million. The acquisition, through CosmoFarm Pharmaceuticals, expands their reach to more than 30 pharmacies, with plans to add 20 more in the region. This follows their recent acquisitions of Bikas GP and Pharmatrade, aiming to increase total annual revenue by over $15 million. CEO Greg Siokas highlighted the importance of this acquisition for sustained profitability and market share growth.

On May 21, 2024, Cosmos Health received an additional delinquency letter from Nasdaq for failing to file its Form 10-Q for Q1 2024 and its Annual Report on Form 10-K for 2023.

The initial failure notice was issued on April 17, 2024, giving the company until June 17, 2024, to submit a plan to regain compliance. If Nasdaq accepts the plan, Cosmos Health could get an extension until October 14, 2024, to meet the compliance requirements. Failure to comply could result in delisting, but the company's shares remain listed for now.

CEO Greg Siokas expressed confidence in regaining compliance. The situation could impact investor confidence and stock performance (NASDAQ: COSM).

Cosmos Health (NASDAQ:COSM) announced its successful participation in Vitafoods Europe 2024, held from May 14 to May 16 at Palexpo, Switzerland. The event, a premier nutraceutical trade show, attracted over 20,000 attendees, more than 50 speakers, and 1,100+ exhibitors from 160+ countries. Cosmos Health showcased its Sky Premium Life nutraceuticals range, receiving significant interest and positive feedback from industry leaders and potential partners. The company connected with numerous organizations, exploring new trends and building partnerships to expand its global business network. CEO Greg Siokas highlighted the event's success in accelerating business growth and enhancing Cosmos Health's international presence.

Cosmos Health, a global healthcare group, received a notification from Nasdaq for the late filing of its Form 10-K. The company is currently non-compliant with Nasdaq Listing Rule 5250(c)(1) but has 60 days to submit a plan to regain compliance. The CEO is optimistic about resolving the issue.

Cosmos Health Inc. announces the development of Cloudscreen 2.0, an advanced AI drug repurposing platform, following the acquisition of Cloudscreen. The new platform utilizes cutting-edge AI and machine learning technologies to predict drug-protein interactions across the human proteome's structural landscape. By integrating mutagenesis data and prediction tools for disordered proteins, Cloudscreen 2.0 aims to revolutionize drug repurposing with more robust predictions and higher confidence scores. Greg Siokas, CEO of Cosmos Health, anticipates significant positive outcomes from Cloudscreen 2.0.

Cosmos Health Inc. announces final stages of securing regulatory approval to sell biocide disinfectant hand soap, C-Scrub Wash 4% CHG, in the UK. The Company expects to enter agreements to supply the NHS, targeting a significant market share. C-Scrub offers immediate and prolonged antimicrobial action, catering to a wide range of microbes, with a focus on skin health and cosmetic friendliness. The global hospital disinfectant market is projected to grow significantly, positioning Cosmos Health for potential growth opportunities.

Cosmos Health Inc. has received regulatory approval to sell its Sky Premium Life vitamins and food supplements in the UAE market, with a projected market growth to $3.94 billion by 2030. The company aims to secure an exclusive distribution agreement and increase revenue through expansion.

Cosmos Health Inc. announces the successful acquisition of Pharmatrade S.A.'s distribution network, aiming to boost 2024 revenue by $5 million and improve operational efficiencies through synergies with CosmoFarm Pharmaceuticals S.A.